OpenAI unveils GPT‑Rosalind for biology

Drug discovery starts with a biology question, like which protein to target, and that early choice can shape a decade of work. OpenAI says its new GPT‑Rosalind model is built to help with that stage. (openai.com) OpenAI introduced GPT‑Rosalind on April 16 and described it as a frontier reasoning model for biology, drug discovery, and translational medicine. The company said the model is optimized for chemistry, protein engineering, genomics, and scientific tool use. (openai.com) (help.openai.com) In drug research, translational medicine means turning lab findings into tests, trials, and treatments that can work in patients. OpenAI said the model is meant for bioinformaticians, computational biologists, and early-discovery teams working through those steps. (help.openai.com) (openai.com) OpenAI said Amgen, Moderna, and Thermo Fisher Scientific are already using GPT‑Rosalind in early programs. Fierce Biotech reported the launch followed OpenAI’s recently announced work with Novo Nordisk. (openai.com) (fiercebiotech.com) The company is not releasing the model as a general public chatbot. OpenAI said GPT‑Rosalind is in research preview and available through a trusted-access process for eligible institutions. (openai.com 1) (openai.com 2) OpenAI framed the pitch around time: it said a new drug in the United States typically takes about 10 to 15 years to move from target discovery to regulatory approval. The company argued that better decisions at the earliest stage can improve downstream experiments and target selection. (openai.com) The launch arrives as other artificial intelligence companies push deeper into biotech. Anthropic acquired stealth startup Coefficient Bio in a reported $400 million stock deal in early April, according to Fierce Biotech and TechCrunch. (fiercebiotech.com) (techcrunch.com) Lantern Pharma, a clinical-stage oncology company, said on April 14 that its withZeta.ai platform was commercially live and opening academic, introductory, and commercial subscriptions. The company pitched it as a multi-agent system for rare-cancer drug discovery and development. (ir.lanternpharma.com) That leaves biotech researchers with a new set of AI products aimed at the same bottleneck: reading huge volumes of biology data, proposing experiments, and narrowing which hypotheses are worth testing in a lab. GPT‑Rosalind is OpenAI’s bid to become one of those tools inside pharmaceutical research teams. (openai.com) (ir.lanternpharma.com) (fiercebiotech.com)